Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Diabetes in Pet Animals
4.2.2 Increase in Pet Adoption
4.2.3 Growing Prevalence of Obesity among Pet Animals
4.3 Market Restraints
4.3.1 High Cost of Diabetes Medications
4.3.2 Adverse Reaction of Medications
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Insulin Therapy
5.1.2 Oral Medication
5.2 By Device Type
5.2.1 Glucose Monitoring Devices
5.2.2 Insulin Delivery Devices
5.3 By Animal Type
5.3.1 Canine
5.3.2 Feline
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allison Medical
6.1.2 Apotex Inc.
6.1.3 Becton, Dickinson and Company
6.1.4 Boehringer Ingelheim Vetmedica Inc.
6.1.5 Henry Schein Animal Health
6.1.6 MED TRUST
6.1.7 Merck & Co. Inc
6.1.8 UltiMed Inc.
6.1.9 Zoetis Inc


7 MARKET OPPORTUNITIES AND FUTURE TRENDS